Meyeon Park1, Eric Vittinghoff2, Michael G Shlipak3, Rakesh Mishra4, Mary Whooley3, Nisha Bansal5. 1. University of California, San Francisco, Division of Nephrology, San Francisco, CA. Electronic address: meyeon.park@ucsf.edu. 2. University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA. 3. University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, CA; San Francisco Veterans Affairs Medical Center, San Francisco, CA; University of California, San Francisco, Department of Medicine, San Francisco, CA. 4. San Francisco Veterans Affairs Medical Center, San Francisco, CA; University of California, San Francisco, Division of Cardiology, San Francisco, CA. 5. University of Washington, Division of Nephrology, Seattle, WA.
Abstract
BACKGROUND: Subclinical volume overload in the absence of diagnosed heart failure (HF) may be an underrecognized contributor to kidney function decline in coronary artery disease (CAD) patients. We evaluated associations of circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of ventricular stretch, with change in estimated glomerular filtration rate (eGFR). METHODS: We evaluated 535 patients with stable CAD and no history of HF, who were enrolled in the Heart and Soul Study and followed for 5 years. N-terminal pro-B-type natriuretic peptide was measured at baseline. We evaluated the associations of NT-proBNP with change in kidney function over 5 years: (a) annual percent change in eGFR, (b) rapid kidney function loss (> 3% per year for 5 years), and (c) incident eGFR < 60 mL/min per 1.73 m2. In multivariable models, we adjusted for demographics, comorbid conditions, echocardiographic parameters, medications, and baseline kidney function. RESULTS: Among 535 participants, median NT-proBNP was 130.6 (interquartile range 61.8-280.9) pg/mL, and median B-type natriuretic peptide (BNP) was 32.5 (14.4-75.9) pg/mL. Individuals with NT-proBNP levels in the highest quartile (> 280.9 pg/mL) had a greater odds of rapid kidney function loss after full adjustment (odds ratio 2.95; 95% CI 1-8.65; P = .0492). Associations with incident eGFR < 60 mL/min per 1.73 m2 were also significant (adjusted odds ratio 4.23; 95% CI 1.05-16.98; P = .0422). Results were similar when analyzed using BNP as the predictor. CONCLUSIONS: N-terminal pro-B-type natriuretic peptide and BNP are strongly and independently associated with accelerated kidney function loss, even in the absence of clinical HF. These findings suggest that subclinical cardiovascular dysfunction may contribute to elevated kidney disease risk in persons with CAD.
BACKGROUND: Subclinical volume overload in the absence of diagnosed heart failure (HF) may be an underrecognized contributor to kidney function decline in coronary artery disease (CAD) patients. We evaluated associations of circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of ventricular stretch, with change in estimated glomerular filtration rate (eGFR). METHODS: We evaluated 535 patients with stable CAD and no history of HF, who were enrolled in the Heart and Soul Study and followed for 5 years. N-terminal pro-B-type natriuretic peptide was measured at baseline. We evaluated the associations of NT-proBNP with change in kidney function over 5 years: (a) annual percent change in eGFR, (b) rapid kidney function loss (> 3% per year for 5 years), and (c) incident eGFR < 60 mL/min per 1.73 m2. In multivariable models, we adjusted for demographics, comorbid conditions, echocardiographic parameters, medications, and baseline kidney function. RESULTS: Among 535 participants, median NT-proBNP was 130.6 (interquartile range 61.8-280.9) pg/mL, and median B-type natriuretic peptide (BNP) was 32.5 (14.4-75.9) pg/mL. Individuals with NT-proBNP levels in the highest quartile (> 280.9 pg/mL) had a greater odds of rapid kidney function loss after full adjustment (odds ratio 2.95; 95% CI 1-8.65; P = .0492). Associations with incident eGFR < 60 mL/min per 1.73 m2 were also significant (adjusted odds ratio 4.23; 95% CI 1.05-16.98; P = .0422). Results were similar when analyzed using BNP as the predictor. CONCLUSIONS: N-terminal pro-B-type natriuretic peptide and BNP are strongly and independently associated with accelerated kidney function loss, even in the absence of clinical HF. These findings suggest that subclinical cardiovascular dysfunction may contribute to elevated kidney disease risk in persons with CAD.
Authors: A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev Journal: Am J Kidney Dis Date: 1999-07 Impact factor: 8.860
Authors: Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort Journal: N Engl J Med Date: 2013-09-05 Impact factor: 91.245
Authors: Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Carmen A Peralta; Eric Vittinghoff; Nisha Bansal; David Jacobs; Paul Muntner; Bryan Kestenbaum; Cora Lewis; David Siscovick; Holly Kramer; Michael Shlipak; Kirsten Bibbins-Domingo Journal: Am J Kidney Dis Date: 2013-03-07 Impact factor: 8.860
Authors: H Yasue; M Yoshimura; H Sumida; K Kikuta; K Kugiyama; M Jougasaki; H Ogawa; K Okumura; M Mukoyama; K Nakao Journal: Circulation Date: 1994-07 Impact factor: 29.690
Authors: Leila R Zelnick; Ronit Katz; Bessie A Young; Adolfo Correa; Bryan R Kestenbaum; Ian H de Boer; Nisha Bansal Journal: Am J Kidney Dis Date: 2017-01-28 Impact factor: 8.860
Authors: Wendy McCallum; Hocine Tighiouart; Jeffrey M Testani; Matthew Griffin; Marvin A Konstam; James E Udelson; Mark J Sarnak Journal: Kidney Int Rep Date: 2020-07-23
Authors: Patrick Ware; Heather J Ross; Joseph A Cafazzo; Chris Boodoo; Mikayla Munnery; Emily Seto Journal: J Med Internet Res Date: 2020-02-08 Impact factor: 5.428